Objectives: Recently, an association between the accessory gene regulator (agr) in Staphylococcus aureus and the development of vancomycin resistance secondary to suboptimal exposure has been demonstrated. We investigated the relationship of vancomycin with and without gentamicin or rifampicin, and daptomycin in the development of resistance in agr groups I and II.
Introduction
The accessory gene regulator (agr) of Staphylococcus aureus is a global regulator that modulates the expression of numerous virulence factors in a growth phase-dependent manner. 1 Previous studies have demonstrated a relationship between loss of agr function in an agr group II strain and attenuated bactericidal activity. Although agr group II isolates predominate in the hospital, we have documented the incorporation of agr group I strains into this setting. 2 We have noted that all agr groups develop intermediate resistance to vancomycin with subtherapeutic exposures, with a higher propensity for dysfunctional isolates to display Mueller -Hinton broth (Difco, Detroit, MI, USA) supplemented with 25 mg/L calcium and 12.5 mg/L magnesium (CAMHB) was used for in vitro pharmacodynamic models and susceptibility testing involving vancomycin with and without gentamicin and rifampicin. Owing to the dependency of daptomycin on calcium for its activity, all simulations with daptomycin were performed in the presence of CAMHB containing 50 mg/L calcium. Colony counts were determined on tryptic soy agar (TSA; Difco). MICs were determined by broth microdilution according to CLSI (formerly NCCLS) standards and confirmed by the Etest. 4 The function of the agr operon was assessed as described previously. 1 A previously described in vitro pharmacodynamic model (250 mL) was utilized and simulations were conducted over 72 h in duplicate to ensure reproducibility. 3, 5 A two-compartment hollow fibre model (FiberCell Systems Inc., Frederick, MD, USA) was used for resistance breakpoint verification experiments. 6 The following regimens were evaluated: vancomycin 62.5-2000 mg every 12 h (fAUC/MIC 24 14-450; t 1/2 6 h); daptomycin 0.75-6 mg/kg every 24 h (fAUC/MIC 24 30 -239; t 1/2 8 h); gentamicin 5 mg/kg every 24 h (C max 15 mg/L; t 1/2 3 h) and rifampicin 300 mg every 8 h (C max 4-5 mg/L; t 1/2 3 h). Protein binding levels of 55% and 92% were utilized for vancomycin-and daptomycin-free concentration exposures, respectively. 5, 7 Antibiotic concentrations were determined in duplicate in each model between 0 and 72 h. Vancomycin and gentamicin concentrations were determined using fluorescence polarization immunoassay (Abbott Diagnostics TDx). Concentrations of daptomycin and rifampicin were determined using a microbioassay with Micrococcus luteus ATCC 9341. 5 For those regimens outside the bioassay range, pharmacokinetics were extrapolated from known regimens. The AUC was determined using the linear trapezoidal method. Differences between regimens in log 10 cfu/mL at 72 h were determined using analysis of variance with Tukey's test for multiple comparisons. For all experiments, a P value of 0.05 was considered statistically significant.
The emergence of resistance was screened for at multiple time points throughout the simulations. Samples were plated on brain heart infusion agar (for vancomycin) or on Mueller -Hinton agar supplemented with 50 mg/L calcium (for daptomycin) containing 3Â and 6Â MIC. Susceptibility was confirmed by the Etest to detect subsequent changes in MIC.
Results and discussion
Pre-exposure MICs of vancomycin for agr I-positive and -null and agr II-positive and -null isolates were 0.75/1 and 1/1 mg/L, respectively. All isolates were susceptible to daptomycin (MIC 0.25 mg/L). Observed pharmacokinetic parameters (+SD) for vancomycin and daptomycin are shown in Table 1 .
The effect of varying vancomycin concentrations on killing and the emergence of resistance in agr-null group II are displayed in Figure 1 . A dose -response relationship was noted throughout the 72 h testing period against all strains tested. An fAUC/MIC of 16.1 resulted in the development of resistance, with detection of 4 -8-fold changes in the MIC with all strains. The agr-null isolates displayed higher MIC changes at this dose when compared with agr-positive isolates, regardless of agr type with MICs as high as 8 mg/L (8-fold) ( Table 1) . Only regimens with an fAUC/MIC greater than 107.0 were able to suppress resistance emergence. The agr-positive isolates displayed up to a 4-fold increase in MIC with an fAUC/MIC of 16.1 and 31.2. Verification of resistance was confirmed in the hollow fibre model by reproducing the lowest concentration that resulted in resistance from the PK/PD model. Resistance breakpoints were Similar results were noted with these regimens in the other isolates. All isolates recovered were susceptible to daptomycin (MIC 1 mg/L). In the hollow fibre model, the fAUC/MIC of 22 had no effect on inoculum reduction, resulting in no changes in the MIC.
Many factors have been associated with vancomycin treatment failures. In one study, higher rates of morbidity were correlated with patients infected with hGISA strains. In addition, these patients were more likely to have a high bacterial load and a low initial vancomycin concentration (trough 10 mg/L). 8 Factors correlating with reduced susceptibility to vancomycin have been verified in other in vivo and in vitro settings. 9 The penetration of vancomycin into sequestered sites of infection such as pneumonia and endocarditis presents a difficult challenge to maintain therapeutic concentrations. 7 Our findings suggest that vancomycin concentrations correlating with an fAUC/MIC of 107.0 (fC min 2.4 mg/L) or lower did not suppress the emergence of resistance in an agr II-null strain. All strains, regardless of agr type and function, exhibited resistance with the fAUC/MIC 16.1 regimen.
The agr group and function has been noted to play an important role in the development of vancomycin heteroresistance. In vitro, hGISA has occurred in agr II-null populations exposed to subtherapeutic vancomycin concentrations, and loss of agr function may prove advantageous for organism survival. 1 We have demonstrated the tendency of increased vancomycin resistance in all agr-null groups.
3 This is important in hospital settings where we have reported that up to 48% of hospital-associated MRSA had defective agr function when compared with only 3.5% of community-associated MRSA strains. 2 In this study, we were able to reduce the emergence of resistance at doses with an fAUC/MIC ! 165.6 and to minimize or eliminate the emergence of vancomycin resistance with the addition of rifampicin or gentamicin. Although controversy exists regarding the risks and benefits of adding gentamicin or rifampicin to vancomycin to improve patient outcome, 10 our results would suggest that these combinations may prevent the emergence of vancomycin resistance secondary to suboptimal exposures in serious infections such as pneumonia, bacteraemia or endocarditis. Suboptimal daptomycin exposures did not result in daptomycin resistance and increased MIC values did not correlate with agr group or function, which may be an advantage to the use of daptomycin against these strains.
The relationship between agr function and daptomycin was important to explore given recent reports suggesting that vancomycin MIC elevations found in GISA strains may correlate with reduced daptomycin susceptibility. It is important to note that our studies found no relationship with agr group or function and daptomycin susceptibility. Although addressing the most clinically relevant MRSA (USA100 agr II and USA300 agr I), this study was limited by not evaluating groups III and IV. The association between agr group, function, vancomycin resistance and potential therapeutic modalities to prevent resistance in S. aureus requires further investigation. Furthermore, the availability of several therapeutic agents to treat MRSA obligates further study to determine specific niches for these drugs with respect to variables such as vancomycin susceptibility, host factors and site of infection.
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